Dyanavel XR Reduces Need for Additional ADHD Medication
Author Information
Author(s): Young Joel L., Powell Richard N., Powell Anna, Welling Lisa L. M., Granata Lauren, Saal Jaime, Nash Margot
Primary Institution: Rochester Center for Behavioral Medicine
Hypothesis
Can Dyanavel XR reduce the need for immediate-release medication supplementation in adults with ADHD?
Conclusion
Dyanavel XR is effective as a standalone treatment for ADHD in adults, leading to fewer patients needing additional medication.
Supporting Evidence
- Dyanavel XR was the only medication that significantly reduced the need for immediate-release supplementation at 90 days.
- Patients on Dyanavel XR showed improved ADHD symptoms regardless of whether they used additional medication.
- The study found a significant association between Dyanavel XR use and reduced IR supplementation.
Takeaway
Dyanavel XR helps adults with ADHD manage their symptoms all day without needing extra medication later.
Methodology
This study analyzed medical records of adults with ADHD who received at least one extended-release psychostimulant for at least six months.
Potential Biases
Potential biases due to the retrospective design and reliance on self-reported measures.
Limitations
The study's observational nature and lack of diversity in the sample limit the generalizability of the findings.
Participant Demographics
The sample included 417 adults, predominantly female (67.3%) and white (95.9%), with a mean age of 36 years.
Statistical Information
P-Value
0.038
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website